Valuation: Viyash Scientific Limited

Market Cap 119B 1.26B 1.09B 1.01B 932M 1.76B 1.78B 11.91B 4.68B 59.74B 4.72B 4.61B 198B P/E 2027 *
32.8x
P/E 2028 * 20.5x
Enterprise Value 119B 1.26B 1.09B 1.01B 932M 1.76B 1.78B 11.91B 4.68B 59.74B 4.72B 4.61B 198B EV / Sales 2027 *
3.06x
EV / Sales 2028 * 2.7x
Free-Float
32.55%
Yield 2027 *
-
Yield 2028 * -
1 day-0.24%
1 week+8.34%
Current month+8.27%
1 month-5.70%
3 months+24.24%
6 months+35.37%
Current year+31.11%
1 week 249.25
Extreme 249.25
276.5
1 month 248.05
Extreme 248.05
291.15
Current year 178.4
Extreme 178.4
297.9
1 year 167.45
Extreme 167.45
297.9
3 years 86.03
Extreme 86.03
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 15/12/2025
Director of Finance/CFO - 31/12/2025
Chief Tech/Sci/R&D Officer - 04/02/2026
Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 24/08/2020
Director/Board Member 57 10/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+8.34%+53.57%+174.99% 1.26B
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
+0.40%+3.62%+47.30%+38.27% 361B
+0.74%-1.06%+35.80%+39.61% 293B
-0.41%-5.53%+8.71%+10.39% 251B
+4.57%+5.21%+35.91%+67.64% 220B
+1.37%-9.91%+2.97%-45.37% 201B
-2.58%-0.73%+17.16%+67.46% 164B
Average +0.70%-2.78%+32.90%+63.23% 359.04B
Weighted average by Cap. +0.83%-3.79%+38.48%+76.25%

Financials

2027 *2028 *
Net sales 38.99B 410M 355M 331M 305M 575M 581M 3.89B 1.53B 19.51B 1.54B 1.51B 64.62B 44.28B 466M 403M 376M 346M 653M 660M 4.42B 1.73B 22.16B 1.75B 1.71B 73.38B
Net income 3.83B 40.3M 34.91M 32.54M 29.93M 56.5M 57.13M 382M 150M 1.92B 151M 148M 6.35B 5.82B 61.23M 53.03M 49.44M 45.47M 85.84M 86.8M 581M 228M 2.91B 230M 225M 9.65B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
06/08/26 272.90 -0.24% 58,342
05/08/26 ₹273.55 +2.66% 150,611
04/08/26 ₹266.45 +0.99% 102,577
03/08/26 ₹263.85 +4.68% 149,920
31/07/26 ₹252.05 +0.06% 33,405
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
273.55INR
Average target price
312.67INR
Spread / Average Target
+14.30%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock